ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elebsiran

Also written as “VIR-2218”, “Elebsiran” and “BRII-835 (VIR-2218)”.

Its studies are mostly in Hepatitis B, Chronic · Hepatitis · Renal Insufficiency · Fibrosis · Hepatitis D, Chronic, led by 3 companies.

Drug pageElebsiran: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 24, 202511 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vir Biotechnologyits history only84 open or runningphase 3since Mar 24, 2025Sep 11, 2018Dec 2026phase 3 · NCT07128550
Brii Biosciencesits history only20 open or runningphase 2since Aug 7, 2020Aug 7, 2020none ahead
Virion Therapeuticsits history only10 open or runningphase 1since Sep 20, 2023Sep 20, 2023none ahead

Also a collaborator on its studies: VBI Vaccines and Alnylam Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2018First study: phase 2 study in Hepatitis B, ChronicNew to Vir BiotechnologyVir Biotechnology · NCT03672188 · 82 enrolled · Australia, Hong Kong, Korea, Republic of and more
  2. May 29, 2020Phase 2 study in Hepatitis B, ChronicVir Biotechnology · NCT04412863 · 84 enrolled · Australia, Hong Kong, Malaysia and more
  3. Aug 7, 2020Brii Biosciences’ first study: phase 2 study in Hepatitis B, ChronicNew to Brii BiosciencesBrii Biosciences · NCT04507269 · 21 enrolled · China
  4. Feb 7, 2021Phase 2 study in Hepatitis B, ChronicBrii Biosciences · NCT04749368 · 91 enrolled · Australia, China, New Zealand and more
  5. Jul 1, 2022Phase 2 study in Hepatitis D, ChronicVir Biotechnology · NCT05461170 · 95 enrolled · Bulgaria, France, Germany and more
  6. Jul 15, 2022Phase 1 study in FibrosisVir Biotechnology · NCT05484206 · 88 enrolled · United States
  7. Jul 21, 2022Named elebsiranINNProposed as its International Nonproprietary Name in WHO's List 127 · before, VIR-2218
  8. Apr 24, 2023Phase 1 study in Renal InsufficiencyVir Biotechnology · NCT05844228 · 28 enrolled · United States
  9. Sep 20, 2023Virion Therapeutics’ first study: phase 1 study in Hepatitis B, ChronicNew to Virion TherapeuticsVirion Therapeutics · NCT06070051 · 35 enrolled · Hong Kong, New Zealand
  10. Mar 24, 2025Phase 3 study in HepatitisVir Biotechnology · NCT06903338 · 124 enrolled · United States, Canada, Georgia and more
  11. Aug 13, 2025Phase 3 study in HepatitisVir Biotechnology · NCT07128550 · 150 enrolled · Austria, France, Germany and more
  12. Aug 19, 2025Phase 2 study in HepatitisVir Biotechnology · NCT07142811 · 100 enrolled · Belgium, Bulgaria, France and more
  13. Nov 17, 2026Primary completion moved from 2026-11 to 2029-03Date moved laterphase 2 · +28 months · NCT07142811

Ahead

  1. Dec 2026Primary completion: phase 3 study in HepatitisVir Biotechnology · NCT07128550
  2. Mar 2029Primary completion: phase 2 study in HepatitisVir Biotechnology · NCT07142811
  3. Nov 2031Primary completion: phase 2 study in Hepatitis D, ChronicVir Biotechnology · NCT05461170

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07142811Hepatitis · Belgium, Bulgaria, France and more2Active, not recruitingVir BiotechnologyMar 2029100
NCT07128550Hepatitis · Austria, France, Germany and more3Active, not recruitingVir BiotechnologyDec 2026150
NCT06903338Hepatitis · United States, Canada, Georgia and more3Active, not recruitingVir BiotechnologySep 30, 2026124
NCT06070051Hepatitis B, Chronic · Hong Kong, New Zealand1CompletedVirion TherapeuticsMar 31, 202635
NCT05844228Renal Insufficiency · United States1CompletedVir BiotechnologyMar 1, 202528
NCT05484206Fibrosis · United States1CompletedVir BiotechnologyDec 9, 202588
NCT05461170Hepatitis D, Chronic · Bulgaria, France, Germany and more2Active, not recruitingVir BiotechnologyNov 203195
NCT04749368Hepatitis B, Chronic · Australia, China, New Zealand and more2CompletedBrii BiosciencesJul 4, 202391
NCT04507269Hepatitis B, Chronic · China2CompletedBrii BiosciencesSep 30, 202121
NCT04412863Hepatitis B, Chronic · Australia, Hong Kong, Malaysia and more2CompletedVir BiotechnologyMar 25, 202484
NCT03672188Hepatitis B, Chronic · Australia, Hong Kong, Korea, Republic of and more2CompletedVir BiotechnologySep 3, 202082

How it is read

Names in the registry

  • “VIR-2218”, 7 entries
  • “Elebsiran”, 3 entries
  • “BRII-835 (VIR-2218)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.